Based on preclinical evidence that the GABA-benzodiazepine (Bz) complex might play a role in pathologic states of anxiety, our original study examined sensitivity to successive injections of IV diazepam in panic disorder patients and controls, using saccadic eye velocity as the major pharmacodynamic measure. In our initial sample, we found reduced Bz effects on saccadic velocity, as well as sedation and memory, in panic disorder patients. Because of less robust panic-control differences in a larger sample of panic patients, intermediate Bz sensitivity values found in a smaller group of generalized anxiety disorder patients and the absence of testing in additional groups of anxious patients, the clinical and diagnostic specificity of this finding is unclear. In addition, because panic patients also showed reduced sedative effects following diazepam, it is possible that differences in saccadic velocity effects are a nonspecific manifestation of differences in arousal between patients and controls rather than a reflection of differences in GABA-Bz complex functioning in brainstem areas controlling saccadic eye velocity. This study will test the diagnostic, clinical and physiologic specificity of reduced Bz sensitivity by employing three major strategies. First, panic patients and controls will be compared to two additional groups of anxious patients (obsessive-compulsive disorder and social phobia). Second, an expanded range of clinical measures will be included to explore clinical correlates of Bz sensitivity across patient groups. Finally, to begin to clarify the physiologic meaning of reduced Bz sensitivity, injections of TRH will be used in panic patients and controls to attenuate the sedative effects of Bzs. Since TRH does not affect Bz-induced saccadic slowing, this intervention will be used to test the hypotheses that panic-control differences in Bz sensitivity (i.e., saccadic slowing) are independent of Bz-induced sedation and persist after TRH has blocked panic-control differences in sedation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH049413-01
Application #
3388771
Study Section
Psychopathology and Clinical Biology Research Review Committee (PCB)
Project Start
1992-04-01
Project End
1994-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Bowdle, T A; Radant, A D; Cowley, D S et al. (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82-8
Radant, A D; Bowdle, T A; Cowley, D S et al. (1998) Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434-44
Roy-Byrne, P; Wingerson, D K; Radant, A et al. (1996) Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry 153:1444-9
Cowley, D S; Roy-Byrne, P P; Radant, A et al. (1995) Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 12:147-57
Cowley, D S; Roy-Byrne, P P; Radant, A et al. (1994) Eye movement effects of diazepam in sons of alcoholic fathers and male control subjects. Alcohol Clin Exp Res 18:324-32